中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2015年
1期
20-20,23
,共2页
美托洛尔%曲美他嗪%心力衰竭%有效性%安全性
美託洛爾%麯美他嗪%心力衰竭%有效性%安全性
미탁락이%곡미타진%심력쇠갈%유효성%안전성
Metoprolol%Trimetazidine%Heart failure%Effectiveness%Security
目的：探讨在冠心病心力衰竭患者中联用美托洛尔及曲美他嗪的有效性及安全性。方法：2011-2013年收治冠心病心力衰竭患者70例，以随机数字表法方式将其分成两组，每组35例。对照组采用美托洛尔治疗，观察组采用美托洛尔联合曲美他嗪治疗，比较两组患者的临床治疗效果。结果：观察组治疗后临床总有效率97.1%，较对照组82.9%高，差异具有统计学意义(P＜0.05)。两组不适症状的发生率较为接近(P＞0.05)。结论：冠心病心力衰竭患者采用美托洛尔联合曲美他嗪治疗，对改善患者心功能有确切效果，且安全可靠，适合在今后的临床上普及应用。
目的：探討在冠心病心力衰竭患者中聯用美託洛爾及麯美他嗪的有效性及安全性。方法：2011-2013年收治冠心病心力衰竭患者70例，以隨機數字錶法方式將其分成兩組，每組35例。對照組採用美託洛爾治療，觀察組採用美託洛爾聯閤麯美他嗪治療，比較兩組患者的臨床治療效果。結果：觀察組治療後臨床總有效率97.1%，較對照組82.9%高，差異具有統計學意義(P＜0.05)。兩組不適癥狀的髮生率較為接近(P＞0.05)。結論：冠心病心力衰竭患者採用美託洛爾聯閤麯美他嗪治療，對改善患者心功能有確切效果，且安全可靠，適閤在今後的臨床上普及應用。
목적：탐토재관심병심력쇠갈환자중련용미탁락이급곡미타진적유효성급안전성。방법：2011-2013년수치관심병심력쇠갈환자70례，이수궤수자표법방식장기분성량조，매조35례。대조조채용미탁락이치료，관찰조채용미탁락이연합곡미타진치료，비교량조환자적림상치료효과。결과：관찰조치료후림상총유효솔97.1%，교대조조82.9%고，차이구유통계학의의(P＜0.05)。량조불괄증상적발생솔교위접근(P＞0.05)。결론：관심병심력쇠갈환자채용미탁락이연합곡미타진치료，대개선환자심공능유학절효과，차안전가고，괄합재금후적림상상보급응용。
Objective:To explore the effectiveness and security of metoprolol combined with trimetazidine in the treatment of coronary heart disease with heart failure.Methods:70 patients of coronary heart disease with heart failure from 2011 to 2013 were divided into two groups by the method of random number table,with 35 cases in each group.The control group were treated with metoprolol,and the observation group were treated with metoprolol combined with trimetazidine.We compared the clinical effect of the two groups.Results:The clinical total effective rate of the observation group(97.1%) after treatment was higher than that of the control group(82.9%),and the difference was statistically significant(P<0.05).The incidence rates of symptoms in the two groups were similar(P>0.05).Conclusion:Metoprolol combined with trimetazidine in the treatment of patients with coronary heart disease and heart failure can improve the cardiac function in patients and is safe and reliable,which is suitable for popularization and application in future clinical.
